Patents by Inventor Jin-Hyung Ahn

Jin-Hyung Ahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11936233
    Abstract: A charging control apparatus measures a first temperature of a first secondary battery selected from the plurality of secondary batteries, a second temperature of a coolant flowing into the cooling device, a charging current of the secondary battery pack, a first terminal voltage of the first secondary battery and a second terminal voltage of a second secondary battery closest to the cooling device, estimates a temperature of a temperature estimation point of the second secondary battery from a lumped thermal model having a thermal resistance between two points selected from the temperature estimation point of the second secondary battery, the first temperature measurement point and the second temperature measurement point, and measurement data about temperature, current and voltage, and determines the estimated temperature as a minimum temperature of the secondary battery pack, and varies a charging power provided to the secondary battery pack according to the minimum temperature.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: March 19, 2024
    Assignee: LG ENERGY SOLUTION, LTD.
    Inventors: Jin-Hyung Lim, Gi-Min Nam, Kyu-Chul Lee, Hyoung Jun Ahn, Won-Tae Joe
  • Patent number: 11915767
    Abstract: A negative voltage switching device includes a first switching circuit configured to transmit a first negative voltage, a second switching circuit configured to transmit a second negative voltage, and a switching selection circuit configured to select one of the first switching circuit or the second switching circuit for transmitting one of the first negative voltage and the second negative voltage to an output terminal.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: February 27, 2024
    Assignee: KEY FOUNDRY CO., LTD.
    Inventors: Jin Hyung Kim, Sung Bum Park, Kee Sik Ahn
  • Publication number: 20190348551
    Abstract: A PERL solar cell and a method for preparing same. In forming a back contact electrode of the PERL solar cell comprising a BSF metal layer and a bus bar electrode, the PERL solar cell has the BSF metal layer provided on opening portions of a passivation layer and has a bus bar electrode formed on the passivation layer, thereby resolving all mechanical defects generated when forming the opening portions of the passivation layer, and enhancing the strength of the solar cell. The PERL solar cell of the present disclosure comprises: a solar cell substrate; a passivation layer provided on one side of the substrate and having a plurality of opening portions which expose the surface of the substrate; a bus bar electrode provided on the passivation layer and on an area not overlapping the area on which the opening portions are provided; and a BSF metal layer provided on the passivation layer so as to fill all the plurality of opening portions.
    Type: Application
    Filed: June 21, 2017
    Publication date: November 14, 2019
    Applicant: Hyundai Heavy Industries Green Energy Co., Ltd.
    Inventors: Jin Hyung Ahn, Jong Keum Lim, Jae Won Seo, Moon Seok Kim, San Il Yoon
  • Patent number: 10184010
    Abstract: The present invention relates to a novel dual-targeting protein comprising: a protein that binds specifically to delta-like ligand 4 (DLL4); and an antibody that binds specifically to vascular endothelial cell growth factor (VEGF).
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: January 22, 2019
    Assignee: ABLBIO
    Inventors: Dong Heon Lee, Kyung Duk Moon, Yu Bin Choi, Kyung Jae Kang, Dong In Kim, Jin Hyung Ahn, Weon Kyoo You, JinWon Jung
  • Publication number: 20160159929
    Abstract: The present invention relates to a novel dual-targeting protein comprising: a protein that binds specifically to delta-like ligand 4 (DLL4); and an antibody that binds specifically to vascular endothelial cell growth factor (VEGF).
    Type: Application
    Filed: July 8, 2014
    Publication date: June 9, 2016
    Inventors: Dong Heon Lee, Kyung Duk Moon, Yu Bin Choi, Kyung Jae Kang, Dong In Kim, Jin Hyung Ahn, Weon Kyoo You, Jinwon Jung
  • Publication number: 20100196370
    Abstract: The present invention relates to an LK8-Fc fusion protein, which has increased angiogenesis inhibitory activity and in vivo stability. More specifically, relates to an LK8-Fc fusion protein in which an LK8 protein having angiogenesis inhibitory activity is fused with the Fc region of human immunoglobulin IgG1, as well as a composition for treating cancer, which contains the fusion protein. The LK8-Fc fusion protein has not only angiogenesis inhibitory activity leading to anticancer and metastasis inhibitory activities, but also a very long in vivo half-life, and thus can be used as a more efficient and economic cancer therapeutic agent or cancer inhibitor.
    Type: Application
    Filed: November 16, 2007
    Publication date: August 5, 2010
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Hyun-Kyung Yu, Yeup Yoon, Jin-Hyung Ahn, In-Hwan Lim, Ho-Jeong Lee, Jang-Seong Kim, Doo-Hong Park
  • Patent number: 7285277
    Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: October 23, 2007
    Assignee: Mogam Biotechnology Research Institute
    Inventors: Jang-Seong Kim, Jin-Hyung Ahn, Hyun-Kyung Yu, Ho-Jeong Lee, Doo-Hong Park, Yeup Yoon
  • Publication number: 20070031379
    Abstract: The present invention relates to an anticancer or an anti-metastatic agent for gene therapy, more precisely, an anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein (a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient, and a treatment method for cancer using the same. The agent for gene therapy of the present invention has an inhibiting effect on the growth and the metastasis of a tumor, so it can be effectively used for the prevention and the treatment of various solid tumors as a metastasis inhibitor or a therapeutic agent for primary tumors.
    Type: Application
    Filed: January 10, 2005
    Publication date: February 8, 2007
    Inventors: Kyu Lee, Hyunkyung Yu, Ho-Jeong Lee, Jin-Hyung Ahn, Jang-Seong Kim, Eui-Cheol Jo, Yeup Yoon, Doo-Hong Park, Seong-Tae Yun
  • Publication number: 20060013823
    Abstract: The present application discloses a method of reducing tumor growth that includes contacting the tumor with a tumor growth reducing effective amount of a composition comprising LK8 or LK68 protein or a functionally equivalent amino acid variant thereof and a pharmaceutically acceptable carrier thereof to a subject having tumor.
    Type: Application
    Filed: September 23, 2005
    Publication date: January 19, 2006
    Applicant: MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE
    Inventors: Jang-Seong KIM, Jin-Hyung AHN, Hyun-Kyung YU, Ho-Jeong LEE, Doo-Hong PARK, Yeup YOON